CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD.

Chongqing Pharscin Pharmaceutical Co., Ltd.

002907

CNE100003308

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
12.54 ^CNY	+2.79%		+0.48%	-18.83%

Jun. 21	Chongqing Pharscin Pharmaceuticals Completes Domestic Production Registration for Hepatitis Drug	MT
Jun. 18	Pharscin Pharma's Vonoprazan Fumarate Tablets Get Registration Certificate from Chinese Drug Regulator	MT

Chongqing Pharscin Pharmaceutical Co., Ltd. Implements 2023 Final Profit Distribution, Payable on 04 June 2024

May 28, 2024 at 03:32 pm EDT

Chongqing Pharscin Pharmaceutical Co., Ltd. implemented 2023 final profit distribution plan: Cash dividend/10 shares (tax included) of CNY 0.50000000 for A share. Record date is 03 June 2024, Ex-date is 04 June 2024 and payment date is 04 June 2024.

Latest news about Chongqing Pharscin Pharmaceutical Co., Ltd.

Chongqing Pharscin Pharmaceuticals Completes Domestic Production Registration for Hepatitis Drug	Jun. 21	MT
Pharscin Pharma's Vonoprazan Fumarate Tablets Get Registration Certificate from Chinese Drug Regulator	Jun. 18	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Implements 2023 Final Profit Distribution, Payable on 04 June 2024	May. 28	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023	May. 22	CI
Pharscin Pharmaceutical Gets Nod to Amend License	May. 16	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 27	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 09	CI
Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets	Apr. 03	MT
Pharscin Pharmaceutical Amends Colon Cleanser Drug's Validity Period	Jan. 24	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Pharscin Pharmaceutical Gets FDA Nod on Buspirone Hydrochloride Tablets	23-10-12	MT
Chongqing Pharscin Pharmaceutical Co., Ltd.(XSEC:002907) added to S&P Global BMI Index	23-09-18	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-20	CI
Pharscin Pharmaceutical Gets Nod to Amend Usage of Bawei Qilong Granules	23-08-18	MT
Pharscin Pharma's Production Base Passes US FDA Inspection	23-07-12	MT
Pharscin Pharma Gets Approval for Supplementary Application of Traditional Chinese Medicine	23-06-12	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Implements Final Cash Dividend of A shares for 2022, Payable on June 13, 2023	23-06-05	CI
Chongqing Pharscin Pharmaceutical Co., Ltd Approves the Cash Dividend for 2022	23-05-22	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Pharscin Pharma Obtains China Marketing Rights to Hypertension Drug; Shares Drop 4%	23-02-20	MT
Pharscin Pharma’s Profit Rises 3.5% in 2022 Despite 7% Drop in Revenue	23-02-13	MT
Chengxin Rating Terminates Pharscin Pharma’s Credit Ratings After Bond Redemption	23-01-04	MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-16	CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Announces Final Profit Distribution on A Shares for the Year 2021, Payable on July 14, 2022	22-07-06	CI

Chart Chongqing Pharscin Pharmaceutical Co., Ltd.

Duration

Period

Chart Chongqing Pharscin Pharmaceutical Co., Ltd.

More charts

Company Profile

Chongqing Pharscin Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs and chemical drugs. The Company operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The Company's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Companyâs products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The Company mainly distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CHONGQING PHARSCIN PHARMACEUTICAL CO., LTD.	-18.83%	700M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.59%	45.93B
OTSUKA HOLDINGS CO., LTD.	+36.11%	23.66B
SANDOZ GROUP AG	+29.93%	16.25B
CIPLA LIMITED	+20.84%	14.63B
ZYDUS LIFESCIENCES LIMITED	+68.80%	14.22B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.31%	6.3B
ASPEN PHARMACARE HOLDINGS LIMITED	+15.26%	5.77B
STADA ARZNEIMITTEL	-8.87%	5.73B